Wegovy (semaglutide injection once weekly) / Novo Nordisk - LARVOL DELTA

Study finds surge in the use of weight loss drugs among bariatric surgery patients (News-Medical) - "The research team performed a cross-sectional study looking at glucagon-like peptide-1 receptor agonists (GLP-1s) semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) among patients undergoing metabolic and bariatric surgery. Dr. Sweigert and colleagues analyzed nearly 365,000 patients who underwent primary metabolic and bariatric surgery between 2018 and 2024....Preliminary findings indicate the proportion of patients receiving at least one GLP-1 prescription in the year leading up to surgery increased from 1.8% in the first quarter of 2020 to 29.4% in the fourth quarter of 2024 - a sixteenfold rise. Use surged across patients with and without diabetes, underscoring the expanding role of these medications in obesity treatment, independent of diabetes status."

Real-world evidence • Obesity • Type 2 Diabetes Mellitus

Costco to sell Ozempic and Wegovy at a large discount for people without insurance (NBC News) - "Novo Nordisk, the company that makes Ozempic and Wegovy, announced Friday it will be selling the prescription injectable pens at the warehouse chain's pharmacies. A four-week supply of the weight loss drug will cost $499 out of pocket...Executive members and those with Costco Citibank credit cards will receive an additional 2% discount....For members who have insurance, the price will depend on their plan."

Commercial • Obesity

CVS PBM Caremark exploring $200 copay for Novo Nordisk's Wegovy - report (MSN News)

US reimbursement • Obesity

LIBERATE-1: Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Vivani Medical, Inc | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt (clinicaltrials.gov) - P2 | N=168 | Completed | Sponsor: Veru Inc. | Active, not recruiting ➔ Completed | Trial completion date: Apr 2025 ➔ Aug 2025 | Trial primary completion date: Dec 2024 ➔ Apr 2025

Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Chong Kun Dang and Korea Novo Nordisk co-sell Wegovy in South Korea starting October (Chosun Biz)

Launch non-US • Obesity

Novo Nordisk Canada and Pocketpills Announce Collaboration to Provide Enhanced Online Pharmacy and Prescription Services and Support for Ozempic and Wegovy (Canada Newswire) - "The service launches across all Canadian provinces and territories – except Quebec – providing millions of Canadians with a modern approach to prescription management."

Commercial • Obesity • Type 2 Diabetes Mellitus

Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress (GlobeNewswire) - "The INFORM real-world evidence study shows impact of semaglutide on reducing ‘food noise’, and the STEP UP clinical trial highlights semaglutide’s effect on control of eating and body composition after losing weight; Next-generation obesity treatment cagrilintide demonstrates promise as standalone therapy (REDEFINE 1); data also being presented on amycretin; The first head-to-head real-world study, REACH shows superiority of Ozempic versus dulaglutide on cardiovascular events such as heart attack and stroke."

Clinical data • Cardiovascular • Obesity • Type 2 Diabetes Mellitus

Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD (GlobeNewswire) - "Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of semaglutide-induced loss of lean mass, while increasing fat mass loss. Numeric improvements in metabolic and lipid parameters including waist circumference, blood pressure, cholesterol, triglycerides and A1C, were observed across all treatment groups."

P2 data • Obesity

The STEP UP Obesity trial enrolled people living with obesity but without Type 2 diabetes. (UT Southwestern Medical Center) - "In this study, nearly a third of patients lost 25% or more of their starting weight on the higher dose of semaglutide, compared with only 15% who lost that amount on 2.4 mg and none on the placebo."

P3 data • Obesity

About 52% of people in Denmark prescribed semaglutide (Ozempic, Wegovy) for weight loss stopped taking it after one year, researchers reported Saturday at a meeting of the European Association for the Study of Diabetes… (United Press International) - "The drugs' high cost appears to be the reason why people give them only a brief try, researchers said. 'This level of drop off is concerning because these medications aren't meant to be a temporary quick fix' lead author...said in a news release."

Clinical data • Obesity

Novo Nordisk…announced results from the US-based INFORM survey of people taking semaglutide for weight management (Wegovy), at the European Association for the Study of Diabetes (EASD) 2025 (GlobeNewswire) - "The number of people who reported experiencing constant thoughts about food throughout the day declined by 46% after starting treatment with Wegovy. The majority of respondents reported improved mental health (64%) and healthier habits (80%) while taking Wegovy."

Real-world • Obesity

Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy (clinicaltrials.gov) - P4 | N=60 | Suspended | Sponsor: The Cleveland Clinic | Phase classification: P=N/A ➔ P4 | N=120 ➔ 60 | Recruiting ➔ Suspended

Enrollment change • Phase classification • Trial suspension • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) - P=N/A | N=30 | Active, not recruiting | Sponsor: Louisiana State University Health Sciences Center in New Orleans | Trial completion date: Jul 2025 ➔ Feb 2026 | Trial primary completion date: Jun 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Inflammation • Obesity

STABLE Wt Loss: Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (clinicaltrials.gov) - P4 | N=120 | Completed | Sponsor: University of Pennsylvania | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

Special Use - Results Surveillance on Long-term Use With Wegovy® (clinicaltrials.gov) - P=N/A | N=1000 | Enrolling by invitation | Sponsor: Novo Nordisk A/S | Trial primary completion date: Jun 2025 ➔ Jan 2028

Real-world evidence • Trial primary completion date • Genetic Disorders • Obesity

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects (clinicaltrials.gov) - P3 | N=420 | Not yet recruiting | Sponsor: Gan & Lee Pharmaceuticals.

New P3 trial • Genetic Disorders • Obesity

SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY® (clinicaltrials.gov) - P=N/A | N=1100 | Completed | Sponsor: Hospices Civils de Lyon | Not yet recruiting ➔ Completed | Trial completion date: Apr 2026 ➔ Jun 2025 | Trial primary completion date: Apr 2026 ➔ Jun 2025

Trial completion • Trial completion date • Trial primary completion date • Binge Eating Disorder • CNS Disorders • Genetic Disorders • Obesity • Sarcopenia • MC4R • PCSK1

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (N Engl J Med, PubMed) - "Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group..."

P3 data • Metabolic Dysfunction-Associated Steatohepatitis

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (N Engl J Med, PubMed) - "Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group..."

P3 data • Metabolic Dysfunction-Associated Steatohepatitis

Wegovy proven effective in East Asians with lower BMI, 1st study confirms (Korea Biomedical Review) - "Specifically, the results showed that by week 44 of the clinical trial, the Wegovy group achieved an average weight reduction of 16.0 percent, significantly outperforming the placebo group (3.1 percent reduction). The waist circumference decreased by 11.9 cm, clearly confirming its effect on reducing abdominal obesity."

Clinical data • Obesity

Novo Nordisk weight-loss injections Saxenda and Wegovy…have been prescribed more than 1.1 million times in Korea over the past five years, according to newly released data. (Korea Biomedical Review) - "Between January 2020 and June 2025, the Drug Utilization Review (DUR) system recorded 721,310 prescriptions for Saxenda and 395,384 for Wegovy, totaling 1,116,694 cases....Regionally, demand was concentrated in metropolitan areas, with 40.2 percent of prescriptions in Seoul and 23.5 percent in Gyeonggi Province."

Commercial • Obesity

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term (clinicaltrials.gov) - P3 | N=600 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

Novo Nordisk's Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease (PRNewswire) - "There were 15 (0.1%) of these cardiovascular events recorded with Wegovy, and 39 events (0.4%) were recorded with tirzepatide. The average follow-up duration was 3.8 months for the Wegovy group and 4.3 months for the tirzepatide group...In all treated people, regardless of any gaps in their treatment, Wegovy showed a significant 29% risk reduction for heart attack, stroke and death from any cause compared with tirzepatide (over an average follow-up of 8.3 months for Wegovy and 8.6 months for tirzepatide)."

Real-world • Cardiovascular • Obesity

Novo Nordisk Partners with Chong Kun Dang for ‘Wegovy’ Boost [Google translation] (Business Korea) - "As Eli Lilly is expected to launch its obesity treatment 'Mounjaro' in Korea in August, competitor Novo Nordisk is forming a strategic alliance with Chong Kun Dang. This move is interpreted as an effort to strengthen domestic sales to counter Eli Lilly, as Mounjaro is known to have superior weight loss effects compared to Novo Nordisk's obesity drug 'Wegovy'."

Launch non-US • Licensing / partnership • Obesity